Discount up to 35% for first purchase only this month.
Discount up to 35% for first purchase only this month.
Tirzepatide is a synthetic dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly — the first-in-class twincretin peptide.
Tirzepatide is a synthetic dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly — the first-in-class twincretin peptide. In Phase 3 SURPASS trials, Tirzepatide achieved up to 22.5% weight loss, surpassing Semaglutide’s results and establishing dual agonism as superior to single GLP-1 activation for metabolic endpoints. It serves as a critical comparator in research between single-mechanism (Semaglutide) and triple-mechanism (Retatrutide) approaches.
Quality Specifications
Purchasers must be 21 years of age or older.
The products shown on this website are intended strictly for laboratory research purposes only and are not for human or animal consumption in any form.